Transcatheter Aortic Valve Replacement to Treat Pure Aortic Regurgitation on Noncalcified Native Valves

No evidence exists on the feasibility of transcatheter aortic valve replacement (TAVR) using balloon-expandable valves to treat pure aortic regurgitation (AR) on noncalcified native valves (NCNV). We report the first experience of TAVR with SAPIEN 3 prostheses (Edwards Lifesciences, Irvine, California) in patients with pure AR on NCNV.

http://ift.tt/2cYicIb